Beta Drugs Bilan de santé
Santé financière contrôle des critères 6/6
Beta Drugs possède un total de capitaux propres de ₹1.8B et une dette totale de ₹190.6M, ce qui porte son ratio d'endettement à 10.5%. Son actif total et son passif total sont ₹2.9B et de ₹1.1B. L'EBIT de Beta Drugs est ₹558.1M ce qui fait que son ratio de couverture des intérêts 27.2. Elle dispose de liquidités et de placements à court terme de ₹278.9M.
Informations clés
10.5%
Ratio d'endettement
₹190.60m
Dette
| Ratio de couverture des intérêts | 27.2x |
| Argent liquide | ₹278.87m |
| Fonds propres | ₹1.81b |
| Total du passif | ₹1.14b |
| Total des actifs | ₹2.95b |
Mises à jour récentes de la santé financière
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Recent updates
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge
Nov 08Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de BETA ( ₹2.1B ) dépassent ses passifs à court terme ( ₹972.5M ).
Passif à long terme: Les actifs à court terme de BETA ( ₹2.1B ) dépassent ses passifs à long terme ( ₹164.0M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: BETA dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de BETA a été réduit de 32.5% à 10.5% au cours des 5 dernières années.
Couverture de la dette: La dette de BETA est bien couverte par le flux de trésorerie opérationnel ( 132.1% ).
Couverture des intérêts: Les paiements d'intérêts de BETA sur sa dette sont bien couverts par l'EBIT ( 27.2 x couverture).